secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2026-08-06T10:34:40+00:00
Accession:  0001628280-26-053791
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q2 2026 revenue $106.3M, net loss $50.8M; pipeline advances with zoci and ZL-1503
--------------------------------------------------------------------------------

- Total revenue $106.3M (down 3% YoY) but product revenue up 11% sequentially; net loss $50.8M ($0.46/ADS) vs $40.7M loss in Q2 2025.
- R&D expenses rose to $61.8M (up 22% YoY) due to licensing fees; cash $717.5M as of June 30, 2026.
- Zoci (DLL3 ADC) received FDA ODD for NECs and Fast Track for epNECs; Phase 1 data at ESMO 2026; registrational Phase 3 planned H2 2026.
- ZL-1503 (IL-13/IL-31Rα) initial Phase 1 data expected H2 2026; KarXT launched in China; TIVDAK approved in China for cervical cancer.
- VYVGART label expanded in US; partner Vertex's pove BLA accepted with PDUFA Nov 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/0001628280-26-053791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer